18 Publications
2023
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029
Salous, Tareq⋅Shukla, Nikhil A⋅Althouse, Sandra K⋅Perkins, Susan M⋅Furqan, Muhammad⋅Leal, Ticiana⋅Traynor, Anne M⋅Feldman, Lawrence E⋅Hanna, Nasser H and Durm, Greg A
Cancer, vol. 129, (no. 2), pp. 264-271, Jan 2023. | Journal Article
2021
Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla, Nikhil Atul⋅Althouse, Sandra⋅Meyer, Zachary⋅Hanna, Nasser and Durm, Greg
Clinical lung cancer, January 23, 2021. | Journal Article
2020
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
Swiecicki, Paul L⋅Durm, Greg⋅Bellile, Emily⋅Bhangale, Apurva⋅Brenner, J Chad and Worden, Francis P
Investigational new drugs, 2020-Jan-24. | Journal Article
 
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Durm, Greg A⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Sadiq, Ahad A⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Zon, Robin T⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Jalal, Shadia I⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Williamson, Michael J⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Adesunloye, Bamidele A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Harb, Wael A⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Walling, Radhika V⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Titzer, Michael L⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser H
Cancer, vol. 126, (no. 19), pp. 4353-4361, Oct 2020. | Journal Article
 
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179
Anouti, Bilal⋅Anouti, Bilal⋅Althouse, Sandra⋅Althouse, Sandra⋅Durm, Greg⋅Durm, Greg⋅Hanna, Nasser and Hanna, Nasser
Clinical Lung Cancer, vol. 21, (no. 3), pp. 293, May 2020. | Journal Article
2019
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence
Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Nguyen, Ryan⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Vater, Laura⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Timsina, Lava R⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Rupp, Katelin⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Wright, Keylee⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Spitznagle, Miranda⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Paul, Brandy⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Carter-Harris, Lisa⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hudmon, Karen S⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Loehrer, Patrick J⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh⋅Ceppa, DuyKhanh and Ceppa, DuyKhanh
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 6578, 2019-05-20. | Journal Article
 
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081
Yan, Melissa⋅Yan, Melissa⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Mamdani, Hirva⋅Mamdani, Hirva⋅Ganti, Apar Kishor⋅Ganti, Apar Kishor⋅Hrinczenko, Borys⋅Hrinczenko, Borys⋅Jabbour, Salma K⋅Jabbour, Salma K⋅Feldman, Lawrence Eric⋅Feldman, Lawrence Eric⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Leal, Ticiana⋅Leal, Ticiana⋅Almokadem, Salah⋅Almokadem, Salah⋅Naidoo, Jarushka⋅Naidoo, Jarushka⋅Fujioka, Naomi⋅Fujioka, Naomi⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 8535, 2019-05-20. | Journal Article
 
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)
Durm, Greg⋅Durm, Greg⋅Hanna, Nasser and Hanna, Nasser
Translational Lung Cancer Research, vol. 8, (no. 4), pp. 542, 2019-08-00. | Journal Article
2018
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081
Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. TPS179, 2018-02-10. | Journal Article
 
Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection
Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Perkins, Susan⋅Perkins, Susan⋅Perkins, Susan⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Kong, Feng-Ming (Spring)⋅Kong, Feng-Ming (Spring)⋅Kong, Feng-Ming (Spring)⋅Birdas, Thomas J⋅Birdas, Thomas J and Birdas, Thomas J
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 8513, 2018-05-20. | Journal Article
 
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179
Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Sadiq, Ahad Ali⋅Sadiq, Ahad Ali⋅Sadiq, Ahad Ali⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jabbour, Salma⋅Jabbour, Salma⋅Jabbour, Salma⋅Zon, Robin⋅Zon, Robin⋅Zon, Robin⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Fisher, William B⋅Fisher, William B⋅Fisher, William B⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Langdon, Robert M⋅Langdon, Robert M⋅Langdon, Robert M⋅Adesunloye, Bamidele⋅Adesunloye, Bamidele⋅Adesunloye, Bamidele⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Gentzler, Ryan D⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 8500, 2018-05-20. | Journal Article
 
Potential risk factors of pneumonitis associated with consolidation pembrolizumab after chemoradiation in unresectable NSCLC patients
Ahmed, Shahid Sattar⋅Ahmed, Shahid Sattar⋅Ahmed, Shahid Sattar⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Donatelli, John⋅Donatelli, John⋅Donatelli, John⋅Yao, Huan⋅Yao, Huan⋅Yao, Huan⋅Liu, Yongmei⋅Liu, Yongmei⋅Liu, Yongmei⋅DesRosiers, Colleen⋅DesRosiers, Colleen⋅DesRosiers, Colleen⋅Liu, Ziyue⋅Liu, Ziyue⋅Liu, Ziyue⋅Kong, Feng Ming⋅Kong, Feng Ming⋅Kong, Feng Ming⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. 167, 2018-02-10. | Journal Article
2017
Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Cheng, Monica⋅Cheng, Monica⋅Cheng, Monica⋅Durm, Greg⋅Durm, Greg⋅Durm, Greg⋅Hanna, Nasser⋅Hanna, Nasser⋅Hanna, Nasser⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Kong, Feng-Ming (Spring)⋅Kong, Feng-Ming (Spring) and Kong, Feng-Ming (Spring)
Future Oncology, vol. 13, (no. 28), pp. 2505, 2017-December-01. | Journal Article
 
Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179
Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Johnson, Cynthia⋅Johnson, Cynthia⋅Johnson, Cynthia⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Jalal, Shadia Ibrahim⋅Sadiq, Ahad Ali⋅Sadiq, Ahad Ali⋅Sadiq, Ahad Ali⋅Jabbour, Salma⋅Jabbour, Salma⋅Jabbour, Salma⋅Zon, Robin⋅Zon, Robin⋅Zon, Robin⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Kloecker, Goetz H⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Reckamp, Karen L⋅Fisher, William B⋅Fisher, William B⋅Fisher, William B⋅Hanna, Nasser H⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 35, (no. 15_suppl), pp. 8523, 2017-05-20. | Journal Article
2016
Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179
Durm, Greg Andrew⋅Durm, Greg Andrew⋅Kio, Ebenezer A⋅Kio, Ebenezer A⋅Fisher, William B⋅Fisher, William B⋅Titzer, Michael L⋅Titzer, Michael L⋅Jabbour, Salma⋅Jabbour, Salma⋅Breen, TIM⋅Breen, TIM⋅Liu, Ziyue⋅Liu, Ziyue⋅Hanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. e20025, 2016-05-20. | Journal Article
 
Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU)
Tatineni, Sushma⋅Tatineni, Sushma⋅Tatineni, Sushma⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Durm, Greg Andrew⋅Kunapareddy, Girish Chandra⋅Kunapareddy, Girish Chandra⋅Kunapareddy, Girish Chandra⋅Ammakkanavar, Natraj Reddy⋅Ammakkanavar, Natraj Reddy⋅Ammakkanavar, Natraj Reddy⋅Dropcho, Edward F⋅Dropcho, Edward F⋅Dropcho, Edward F⋅Althouse, Sandra⋅Althouse, Sandra⋅Althouse, Sandra⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Hanna, Nasser H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Einhorn, Lawrence H⋅Albany, Costantine⋅Albany, Costantine and Albany, Costantine
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. e16052, 2016-05-20. | Journal Article
2015
An update on current standards and clinical trials in systemic therapy for stage III NSCLC
Durm, Greg⋅Durm, Greg⋅Hanna, Nasser and Hanna, Nasser
Lung Cancer Management, vol. 4, (no. 6), pp. 297, 2015-December-01. | Journal Article
2014
Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer
Durm, Greg⋅Durm, Greg⋅Hanna, Nasser and Hanna, Nasser
Future Oncology, vol. 10, (no. 7), pp. 1173, 2014-May-01. | Journal Article